PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26217035-0	2015	c-Abl-mediated tyrosine phosphorylation of JunB is required for Adriamycin-induced expression of p21.	Doxorubicin	64-74	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	0-5	
26217035-6	2015	Because c-Abl promotes expression of the cyclin-dependent kinase inhibitor p21 upon stimulation with the DNA-damaging agent Adriamycin (doxorubicin), we analysed the involvement of JunB in Adriamycin-induced p21 expression.	Doxorubicin	124-134	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	8-13	
26217035-6	2015	Because c-Abl promotes expression of the cyclin-dependent kinase inhibitor p21 upon stimulation with the DNA-damaging agent Adriamycin (doxorubicin), we analysed the involvement of JunB in Adriamycin-induced p21 expression.	Doxorubicin	136-147	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	8-13	
26217035-6	2015	Because c-Abl promotes expression of the cyclin-dependent kinase inhibitor p21 upon stimulation with the DNA-damaging agent Adriamycin (doxorubicin), we analysed the involvement of JunB in Adriamycin-induced p21 expression.	Doxorubicin	189-199	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	8-13	
26217035-11	2015	Taken together, these results suggest that, although JunB represses p21 promoter activity, c-Abl phosphorylates JunB and conversely inhibits its suppressive role on p21 promoter activity upon Adriamycin stimulation.	Doxorubicin	192-202	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	91-96	
26217035-12	2015	Therefore JunB is likely to be a key target of c-Abl in expression of p21 in Adriamycin-induced DDR.	Doxorubicin	77-87	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	47-52